How GE HealthCare’s (GEHC) Growth Target Stands Out After Margin Pressures and Quarterly Profit Dip

• GE HealthCare Technologies Inc. reported its third-quarter and nine-month 2025 earnings, with revenue rising to US$5.14 billion and US$14.93 billion, respectively, while net income for the quarter declined to US$446 million from the previous year.

• The company reaffirmed its full-year 2025 organic revenue growth target despite ongoing concerns around trade pressures and margin challenges.

• We’ll explore how the reaffirmed annual growth guidance in the face of trade challenges may shape GE HealthCare Technologies’ outlook.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.

To be a shareholder in GE HealthCare Technologies, you need to believe in the company’s ability to generate steady revenue growth through innovative healthcare products and partnerships, despite significant risks from global trade tensions and compressed margins. The recent reaffirmation of full-year organic revenue growth guidance is a signal that short-term catalysts, such as product rollouts and market expansions, remain intact, while the most important risk, potential impacts from escalating U.S.–China tariffs, appears unchanged and remains material.

Among recent announcements, the update on the share buyback program stands out as the most relevant. The company completed US$200 million in buybacks over two quarters, reflecting efforts to return value to shareholders even as margin pressures persist and cash flow remains under scrutiny due to tariff impacts. This action aligns with the need for financial discipline amid the ongoing search for earnings stability and growth catalysts.

In sharp contrast, investors should pay close attention to how ongoing tariff pressures could influence future margin performance and free cash flow…

Read the full narrative on GE HealthCare Technologies (it’s free!)

GE HealthCare Technologies’ narrative projects $22.7 billion revenue and $2.5 billion earnings by 2028. This requires 4.3% yearly revenue growth and a $0.3 billion earnings increase from $2.2 billion.

Uncover how GE HealthCare Technologies’ forecasts yield a $86.96 fair value, a 19% upside to its current price.

Four individual fair value estimates from the Simply Wall St Community place GE HealthCare between US$62.11 and US$123.54. While most see current trade headwinds as a material risk, these opinions show how differently market participants are evaluating the company’s future; consider reviewing several perspectives before deciding your view.

Explore 4 other fair value estimates on GE HealthCare Technologies – why the stock might be worth 15% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GEHC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]